- RepliMoney Group (Nasdaq: Reply) announced that the US Food and Drug Administration has accepted a biosimilar license application for RP1 in combination with nivolumab for patients with advanced melanoma.
- The FDA granted BLA priority review to the prescription drug user
Contents
Related posts:
Say Job City in Pakistan for today latest jobs opportunities in private and Govt departments. View all new Government careers collected from daily. sayjobcity.com